You are here

Gilead prices Covid-19 drug candidate remdesivir at US$2,340 per patient

[CALIFORNIA] Gilead Sciences has priced its Covid-19 drug candidate remdesivir at US$2,340 for a five-day treatment in the United States and some other developed countries, it said on Monday, as it set the price for a single vial at US$390.

The price for US private insurance companies...

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes